From the molecule to the patient

The “Streinth” laboratory aims at developing a dynamic translational research on cancers through an interactive group of scientists and clinicians affiliated to INSERM, Strasbourg Cancer Institute (ICANS), and Strasbourg University Hospitals.

Our goal is to propose innovative and more efficient treatments by deciphering the causes that underlie the variability in therapeutic responses. Our strategy is to characterise the impact of the chemo/chemo-radiation therapies on the interactions between the cancer cells and their specific metabolic (i.e., hypoxie, low pH) and cellular (i.e. immune & neuronal cells) ecosystem with the objective of discovering key effectors of molecular stress pathways that might represent prognostic markers and/or drugable targets. More precisely, we are analysing the contribution of epigenetic processes in the interplay between metabolic stress response pathways activated by the microenvironment and gene regulations driven by the complex family of the p53 tumor suppressor gene (p53, p63, p73). We are focusing more particularly on epidermoid cancers of the aero-digestive system (i.e., gastric, oesophagus, head & neck) as wekk as healthy tissues (ENS, muscles) thar are affected by the therapies.

from the molecule to the patient
Scroll to top